Yana Rubiyana
Research Subjects
Yana Rubiyana has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Andri Wardiana
Research Center for Genetic Engineering, Indonesian National Research and Innovation Agency (BRIN), Cibinong 16911, Indonesia
2 shared publications - Azzania Fibriani
School of Life Sciences and Technology, Bandung Institute of Technology, Bandung, Indonesia
2 shared publications - Dian Fitria Agustiyanti
Research Center for Genetic Engineering, Indonesian National Research and Innovation Agency (BRIN), Cibinong 16911, Indonesia
2 shared publications - Ernawati Arifin Giri-Rachman
School of Life Science and Technology, Institut Teknologi Bandung, Bandung 40132, Indonesia
2 shared publications - Ferry Iskandar
Department of Physics, Faculty of Mathematics and Natural Sciences, Institut Teknologi Bandung, Bandung, Indonesia
2 shared publications - Fitri Aulia Permatasari
Department of Physics, Faculty of Mathematics and Natural Sciences, Institut Teknologi Bandung, Bandung 40132, Indonesia. Collaboration Research Center for Advanced Energy Materials, National Research and Innovation Agency, Institut Teknologi Bandung, Bandung 40132, Indonesia, Research Center for Chemistry, National Research and Innovation Agency (BRIN), Serpong 15314, Indonesia
2 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Bogor Agricultural University in HAYATI Journal of Biosciences
- Vol. 33 (6) , 1451-1459
Evaluation of Carbon-Dots (CDs) as Antiviral Candidates Against SARS-CoV-2 Using a Chemical Crosslinking Method
The chemical crosslinking method has been effective in previous studies for interaction-based drug screening. Although CDs have been widely explored as antiviral candidates, studies that use chemical crosslinking to select effective CDs against SARS-CoV-2 remain limited. To address this gap, this study uses chemical crosslinking to test CDs as antiviral compounds. The objective of this study is to screen and determine the potential of CDs as candidate antiviral compounds for inhibiting the dimerization of the SARS-CoV-2 N-CTD protein using a chemical crosslinking method. Recombinant SARS-CoV-2 N-CTD protein was expressed, purified, and precipitated for compound testing with chemical crosslinking. The concentration ranges used in the dimerization inhibition testing were 0-2,000 ppm (pyrrolic-N CDs) and 0-6,000 ppm (pyridinic-N, graphitic-N, and nuciferine-derived CDs). The study’s results show that CDs have the potential to inhibit dimerization of the SARS-CoV-2 N-CTD protein. Among the four compounds tested, pyrrolic-N CDs showed the best inhibitory potential, as they inhibited dimerization at the lowest concentration (2,000 ppm), had the smallest percentage of dimer bands to total protein, and achieved the highest dimerization inhibition efficiency. However, further research, including in vitro and in vivo tests, is needed to comprehensively evaluate the potential of pyrrolic-N CDs.
- 31 October 2026
- Published by Bogor Agricultural University in HAYATI Journal of Biosciences
- Vol. 33 (6) , 1451-1459
Open AccessEvaluation of Carbon-Dots (CDs) as Antiviral Candidates Against SARS-CoV-2 Using a Chemical Crosslinking Method
The chemical crosslinking method has been effective in previous studies for interaction-based drug screening. Although CDs have been widely explored as antiviral candidates, studies that use chemical crosslinking to select effective CDs against SARS-CoV-2 remain limited. To address this gap, this study uses chemical crosslinking to test CDs as antiviral compounds. The objective of this study is to screen and determine the potential of CDs as candidate antiviral compounds for inhibiting the dimerization of the SARS-CoV-2 N-CTD protein using a chemical crosslinking method. Recombinant SARS-CoV-2 N-CTD protein was expressed, purified, and precipitated for compound testing with chemical crosslinking. The concentration ranges used in the dimerization inhibition testing were 0-2,000 ppm (pyrrolic-N CDs) and 0-6,000 ppm (pyridinic-N, graphitic-N, and nuciferine-derived CDs). The study’s results show that CDs have the potential to inhibit dimerization of the SARS-CoV-2 N-CTD protein. Among the four compounds tested, pyrrolic-N CDs showed the best inhibitory potential, as they inhibited dimerization at the lowest concentration (2,000 ppm), had the smallest percentage of dimer bands to total protein, and achieved the highest dimerization inhibition efficiency. However, further research, including in vitro and in vivo tests, is needed to comprehensively evaluate the potential of pyrrolic-N CDs.
- Open Access
- 24 October 2025
- Published by Bogor Agricultural University in HAYATI Journal of Biosciences
- Vol. 33 (1) , 232-239
Evaluation of Curcumin-derived Carbon-dots' Inhibitory Activity as SARS-CoV-2 Antiviral Candidate Using Chemical Crosslinking
In our previous work, we demonstrated that curcumin-derived carbon dots (Cur-CDs) have potential as antivirals for COVID-19. However, the precise mechanism of action remains unclear. This study investigated the potential of Cur-CDs against SARS-CoV-2 by targeting the dimerization of the C-terminal domain of nucleocapsid protein (N-CTD) using chemical crosslinking. Recombinant SARS-CoV-2 N-CTD was expressed, purified, and subjected to chemical crosslinking. The dimerization inhibition ability of Cur-CDs was assessed with ligand concentrations ranging from 0 to 2,000 μg/mL. Successful inhibition —defined as a noticeable reduction in SARS-CoV-2 N-CTD dimer band intensity on SDS-PAGE—was observed when Cur-CDs were present at 8 to 16 times the protein concentration. We hypothesize that Cur-CDs bind to the dimerization residues, preventing non-covalent interactions between monomers and limiting dimer formation. Our findings suggest that Cur-CDs could be a promising antiviral strategy for SARS-CoV-2, especially targeting the dimerization of the nucleocapsid protein. Additionally, this study also highlights the use of chemical crosslinking as a valuable tool for interaction-based drug screening.
- 24 October 2025
- Published by Bogor Agricultural University in HAYATI Journal of Biosciences
- Vol. 33 (1) , 232-239
Open AccessEvaluation of Curcumin-derived Carbon-dots' Inhibitory Activity as SARS-CoV-2 Antiviral Candidate Using Chemical Crosslinking
In our previous work, we demonstrated that curcumin-derived carbon dots (Cur-CDs) have potential as antivirals for COVID-19. However, the precise mechanism of action remains unclear. This study investigated the potential of Cur-CDs against SARS-CoV-2 by targeting the dimerization of the C-terminal domain of nucleocapsid protein (N-CTD) using chemical crosslinking. Recombinant SARS-CoV-2 N-CTD was expressed, purified, and subjected to chemical crosslinking. The dimerization inhibition ability of Cur-CDs was assessed with ligand concentrations ranging from 0 to 2,000 μg/mL. Successful inhibition —defined as a noticeable reduction in SARS-CoV-2 N-CTD dimer band intensity on SDS-PAGE—was observed when Cur-CDs were present at 8 to 16 times the protein concentration. We hypothesize that Cur-CDs bind to the dimerization residues, preventing non-covalent interactions between monomers and limiting dimer formation. Our findings suggest that Cur-CDs could be a promising antiviral strategy for SARS-CoV-2, especially targeting the dimerization of the nucleocapsid protein. Additionally, this study also highlights the use of chemical crosslinking as a valuable tool for interaction-based drug screening.